Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
1. A method comprising
periodically detecting, in a sample of nucleic acids from a subject, nucleic acids that encode one or more mutations in exon 12 of an NPM gene,
wherein the subject has undergone therapy for acute myeloid leukemia characterized by a cytoplasmic location of a nucleophosmin protein (NPM), wherein the subject has completed induction therapy and is under complete hematological remission;
wherein the nucleic acids encoding the one or more mutations encode a signal motif of nuclear export (NES) in the C-terminal region of the NPM gene, and
wherein said detecting comprises identifying the nucleic acids encoding the one or more mutations in the sample using
(a) oligonucleotide primers in a polymerase chain reaction assay that amplifies a nucleic acid encoding the one or more mutations but does not substantially amplify a nucleic acid encoding a wild-type NPM, or
(b) an oligonucleotide probe that binds, in a hybridization assay, to a nucleic acid encoding the one or more mutations but not to a wild-type NPM.
2. The method of claim 1 , wherein the nucleic acid encoding the one or more mutations comprises an exon 12 sequence coding for position 290 of human NPM protein, wherein a mutation in the NPM gene results in a loss of a tryptophan at amino acid position 290.
3. The method of claim 1 , wherein NES comprises an amino acid sequence LxxxVxxVxL (SEQ ID NO:1), wherein x can be any amino acid.
4. The method of claim 3 , wherein the LxxxVxxVxL (SEQ ID NO:1) is LCLAVEEVSL (SEQ ID NO:6); LCMAVEEVSL (SEQ ID NO:7); LCVAVEEVSL (SEQ ID NO:8); LSRAVEEVSL (SEQ ID NO:9); LCTAVEEVSL (SEQ ID NO:11); LSQAVEEVSL (SEQ ID NO: 10); LCHAVEEVSL (SEQ ID NO: 12); LCRAVEEVSL (SEQ ID NO: 13); LCRGVEEVSL (SEQ ID NO: 14); LCQAVEEVSL (SEQ ID NO:15); LCAAVEEVSL (SEQ ID NO:16); or LCKAVEEVSL (SEQ ID NO:17).
5. The method of claim 1 , wherein the NES comprises an amino acid sequence) LxxxLxxVxL (SEQ ID NO:2), wherein the LxxxLxxVxL (SEQ ID NO:2) is LWQSLAQVSL (SEQ ID NO:18); LWQSLEKVSL (SEQ ID NO:19); LWQSLSKVSL (SEQ ID NO: 20); or LCTFLEEVSL (SEQ ID NO:21).
6. The method of claim 1 , wherein the NES comprises an amino acid sequence LxxxFxxVxL (SEQ ID NO:3), wherein the LxxxFxxVxL (SEQ ID NO:3) is LWQCFAQVSL (SEQ ID NO:22); LWQCFSKVSL (SEQ ID NO:23); LWQRFQEVSL (SEQ ID NO:24); or LWQDFLNRL (SEQ ID NO:25).
7. The method of claim 1 , wherein the NES comprises an amino acid sequence LxxxMxxVxL (SEQ ID NO:4), wherein the LxxxMxxVxL (SEQ ID NO:4) is LWQSMEEVSL (SEQ ID NO:26) or LWQRMEEVSL (SEQ ID NO:27).
8. The method of claim 1 , wherein the NES comprises an amino acid sequence LWQCCSQVSL (SEQ ID NO:28).
9. The method of claim 2 , wherein the nucleic acid encoding the one or more mutations comprises an exon 12 sequence coding for positions 288 and 290 of human NPM protein, wherein the mutation in the NPM gene also results in a loss of a tryptophan at amino acid position 288.
10. A method comprising
periodically detecting, in a sample of nucleic acids from a subject, nucleic acids that encode one or more mutations in exon 12 of an NPM gene,
wherein the subject has undergone therapy for acute myeloid leukemia characterized by a cytoplasmic location of a nucleophosmin protein (NPM), wherein the subject has completed induction therapy and is under complete hematological remission;
wherein the nucleic acids encoding the one or more mutations comprise an exon 12 sequence coding for position 290 of human NPM protein, wherein the one or more mutations in the NPM gene results in a loss of a tryptophan at amino acid position 290, and
wherein said detecting comprises identifying the nucleic acids encoding the one or more mutations in the sample using
(a) oligonucleotide primers in a polymerase chain reaction assay that amplifies a nucleic acid encoding the one or more mutations but does not substantially amplify a nucleic acid encoding a wild-type NPM, or
(b) an oligonucleotide probe that binds to a nucleic acid encoding the one or more mutations but not to a wild-type NPM.
11. The method of claim 10 , wherein the nucleic acid encoding the one or more mutations encodes a signal motif of nuclear export (NES) in the C-terminal region of the NPM gene.
12. The method of claim 10 , wherein the nucleic acid encoding the one or more mutations comprises an exon 12 sequence coding for positions 288 and 290 of human NPM protein, wherein the mutation in the NPM gene also results in a loss of a tryptophan at amino acid position 288.
13. The method of claim 11 , wherein the NES comprises an amino acid sequence LxxxVxxVxL (SEQ ID NO:1), wherein x can be any amino acid.
14. The method of claim 13 , wherein the LxxxVxxVxL (SEQ ID NO:1) is LCLAVEEVSL (SEQ ID NO:6); LCMAVEEVSL (SEQ ID NO:7); LCVAVEEVSL (SEQ ID NO:8); LSRAVEEVSL (SEQ ID NO:9); LCTAVEEVSL (SEQ ID NO:11); LSQAVEEVSL (SEQ ID NO: 10); LCHAVEEVSL (SEQ ID NO: 12); LCRAVEEVSL (SEQ ID NO: 13); LCRGVEEVSL (SEQ ID NO: 14); LCQAVEEVSL (SEQ ID NO:15); LCAAVEEVSL (SEQ ID NO:16); or LCKAVEEVSL (SEQ ID NO:17).
15. The method of claim 11 , wherein the NES comprises an amino acid sequence) LxxxLxxVxL (SEQ ID NO:2), wherein the LxxxLxxVxL (SEQ ID NO:2) is LWQSLAQVSL (SEQ ID NO:18); LWQSLEKVSL (SEQ ID NO:19); LWQSLSKVSL (SEQ ID NO: 20); or LCTFLEEVSL (SEQ ID NO:21).
16. The method of claim 11 , wherein the NES comprises an amino acid sequence LxxxFxxVxL (SEQ ID NO:3), wherein the LxxxFxxVxL (SEQ ID NO:3) is LWQCFAQVSL (SEQ ID NO:22); LWQCFSKVSL (SEQ ID NO:23); LWQRFQEVSL (SEQ ID NO:24); or LWQDFLNRL (SEQ ID NO:25).
17. The method of claim 11 , wherein the NES comprises an amino acid sequence LxxxMxxVxL (SEQ ID NO:4), wherein the LxxxMxxVxL (SEQ ID NO:4) is LWQRMEEVSL (SEQ ID NO:26) or LWQRMEEVSL (SEQ ID NO:27).
18. The method of claim 11 , wherein the NES comprises an amino acid sequence LWQCCSQVSL (SEQ ID NO:28).